BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 20796165)

  • 1. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
    Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
    J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcranial doppler quantification of residual shunt after percutaneous patent foramen ovale closure: efficacy of the GORE(®) HELEX septal occluder.
    Sorensen SG; Smout R; Spruance SL
    J Interv Cardiol; 2011 Aug; 24(4):366-72. PubMed ID: 21492220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
    Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
    EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of secondary source of right-to-left shunt with balloon occlusion of patent foramen ovale and power M-mode transcranial Doppler.
    Jesurum JT; Fuller CJ; Renz J; Krabill KA; Spencer MP; Reisman M
    JACC Cardiovasc Interv; 2009 Jun; 2(6):561-7. PubMed ID: 19539262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure: correlation of device efficacy with intracardiac anatomic measures.
    Sorensen SG; Spruance SL; Smout R; Horn S
    J Interv Cardiol; 2012 Jun; 25(3):304-12. PubMed ID: 22364421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of residual shunt rates in five devices used to treat patent foramen ovale.
    Matsumura K; Gevorgyan R; Mangels D; Masoomi R; Mojadidi MK; Tobis J
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):455-63. PubMed ID: 24550064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta-Analysis to Identify the Best Device.
    Varotto L; Bregolin G; Paccanaro M; De Boni A; Bonanno C; Perini F
    Cerebrovasc Dis; 2020; 49(2):124-134. PubMed ID: 32289794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcranial Doppler is Complementary to Echocardiography for Detection and Risk Stratification of Patent Foramen Ovale.
    Tobe J; Bogiatzi C; Munoz C; Tamayo A; Spence JD
    Can J Cardiol; 2016 Aug; 32(8):986.e9-986.e16. PubMed ID: 26952158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
    Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
    Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
    Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
    JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale.
    Gevorgyan Fleming R; Kumar P; West B; Noureddin N; Rusheen J; Aboulhosn J; Tobis JM
    Catheter Cardiovasc Interv; 2020 Feb; 95(3):365-372. PubMed ID: 31654558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
    Susuri N; Obeid S; Ulmi M; Siontis GCM; Wahl A; Windecker S; Nietlispach F; Meier B; Praz F
    EuroIntervention; 2017 Sep; 13(7):858-866. PubMed ID: 28437244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events.
    Wawrzyńczyk M; Gałeczka M; Karwot B; Knop M; Białkowski J
    Kardiol Pol; 2016; 74(4):385-9. PubMed ID: 26412471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
    Aral M; Mullen M
    Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
    Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
    J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).
    Pezzini A; Grassi M; Lodigiani C; Patella R; Gandolfo C; Zini A; DeLodovici ML; Paciaroni M; Del Sette M; Toriello A; Musolino R; Calabrò RS; Bovi P; Adami A; Silvestrelli G; Sessa M; Cavallini A; Marcheselli S; Marco Bonifati D; Checcarelli N; Tancredi L; Chiti A; Del Zotto E; Tomelleri G; Spalloni A; Giorli E; Costa P; Giacalone G; Ferrazzi P; Poli L; Morotti A; Piras V; Rasura M; Simone AM; Gamba M; Cerrato P; Zedde ML; Micieli G; Melis M; Massucco D; Guido D; De Giuli V; Bonaiti S; D'Amore C; La Starza S; Iacoviello L; Padovani A;
    Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices.
    Shafi NA; McKay RG; Kiernan FJ; Silverman IE; Ahlquist M; Silverman DI
    Int J Cardiol; 2009 Nov; 137(3):314-6. PubMed ID: 19616327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla
    Neuser J; Akin M; Bavendiek U; Kempf T; Bauersachs J; Widder JD
    BMC Cardiovasc Disord; 2016 Nov; 16(1):217. PubMed ID: 27832757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.